SCHEMBL2942546

SCHEMBL2942546

CS(=O)(=O)Nc1cccc(-c2cnc3ccc(NCCc4cccnc4)nn23)c1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FYN P06241 15/20 0.64
PIM1 P11309 1/20 0.64
PIK3CD O00329 1/20 0.57
PIK3R1 P27986 1/20 0.57
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.49
MKNK1 Q9BUB5 1/20 0.48
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950672 0.85 MKNK1 (0.69) FYNMKNK1
SCHEMBL2949668 0.84 FYN (0.67) FYNPIM1CYP1A2CYP3A4CYP2D6
SCHEMBL2944991 0.83 FYN (0.68) FYNMKNK1
SCHEMBL2948911 0.83 FYN (0.62) FYNPIM1CYP1A2CYP3A4ALDH1A1
SCHEMBL13234372 0.82 PIM1 (0.74) FYNPIM1PIK3CDPIK3R1MKNK1
SCHEMBL2945203 0.82 PIM1 (0.71) FYNPIM1PIK3CDPIK3R1MKNK1
SCHEMBL2943040 0.82 PIK3CD (0.70) FYNPIM1PIK3CDPIK3R1MKNK1
SCHEMBL2944080 0.80 PIM1 (0.76) FYNPIM1PIK3CDPIK3R1MKNK1
SCHEMBL2948086 0.79 PIM1 (0.68) FYNPIM1
SCHEMBL1054752 0.79 PIK3CD (0.72) FYNPIM1PIK3CDPIK3R1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885PIM1 365/4885PIK3CD 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.